The two extensive datasets include:

• A large-scale functional聽genomics dataset from primary human hepatocytes, created by systematically knocking down all known hepatocyte genes in multiple donors and profiling downstream effects with RNA sequencing.
• A single-cell聽dataset built from perfused human donor livers, capturing gene expression across different cell types and donors.

The collaboration now transitions into a multi-year co-exclusive license agreement, granting both parties the ability to use Ochre-generated proprietary human liver data to accelerate the discovery and development of new treatments for liver diseases.

Ochre’s proprietary OBELiX software further integrates these datasets with proprietary disease atlases, combining gene perturbation data with clinical phenotypes. Together, these resources enable a causal mapping of gene function to proprietary disease signatures across pathways and cell types.

By revealing how different liver cell populations contribute to liver disease progression, the collaboration provides foundational data for training AI models and understanding promising therapeutic targets.

Quin Wills, founder and CEO of 91制片厂 said: “To develop therapies that truly impact the lives of liver patients, we cannot compromise on building large-scale human datasets. Datasets that move beyond population genetics, allowing us to causally explore the complexities of human disease biology. These foundational datasets developed with GSK feed our algorithms (AI) to do just that.”

Kaivan Khavandi, SVP, Head of Respiratory, Immunology & Inflammation at GSK said: “Our collaboration with Ochre has generated data that supports our deepened understanding of human biology and disease. This data feeds our AI models and helps power our work to discover and develop new medicines for liver diseases for patients who are waiting.”

About 91制片厂

91制片厂 is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. 91制片厂 is headquartered in Oxford, UK, and has research labs in New York and Taipei.

Media Contact:

ochre@coulsonpartners.com             +44 7752 329 851

The post 91制片厂 Completes Human Liver Functional Genomics and Single-cell Datasets in Partnership with GSK appeared first on 91制片厂.

announced today that it has completed a sublease for growing U.K.-based biotech company 91制片厂 at 430 East 29th St. within the Alexandria Center^庐 for Life Science 鈥� New York City.

Backed by a $1 billion funding partnership with German pharmaceutical giant Boehringer Ingelheim, 91制片厂 is considered a game-changer in the biotech sector for the way it is rethinking how we understand and treat liver disease 鈥� with the potential to save lives and reduce the need for liver transplants. 

It will relocate from the BioLabs incubator at 180 Varick St. to occupy 5,894 square feet of lab and office space on the sixth floor of the West Tower at the Alexandria Center^庐, the state-of-the-art research and development campus that serves as the flagship location for New York City’s leading life science companies. The Alexandria Center^庐 will house Ochre鈥檚 late-stage validation facilities, the largest ex-vivo machine perfusion laboratory of human donor livers in the world, where the company鈥檚 novel RNA therapies will be validated prior to entering clinical trials.

鈥淲e are thrilled to be planting a flag at the Alexandria Center^庐 for Life Science,鈥� said Quin Wills, CEO and Founder of 91制片厂. 鈥淎 few years ago, we took a bet on NYC as our US site and are now doubling down on one of the world鈥檚 most dynamic biotech and clinical hubs. Our new, larger NYC site will support late-stage validation of our therapies as part of our ambitious clinical goals over the next few years.鈥�

Innovating at the vanguard and heart of New York City’s life science ecosystem, Alexandria has been catalyzing and growing the cluster through the development and operation of the city’s first and only commercial life science campus at the Alexandria Center^庐 for Life Science 鈥� New York City and through the company’s leading venture investment platform and unparalleled ecosystem-building expertise. Located on Manhattan’s East Side Medical Corridor, the Alexandria Center^庐 for Life Science鈥�� New York City offers unique proximity to the City’s top academic medical institutions and major hospitals, and provides a campus setting with robust amenities that create a vibrant ecosystem, attract top-tier talent, and bring together high-quality life science companies to translate scientific discoveries into new treatments and cures for patients. 

A JLL team including Executive Vice President Bill Harvey, Senior Vice President John Cahill and Associate Vice President Thomas Burrus, represented both 91制片厂 and the unnamed sublandlord in this transaction. The deal is the second relocation from BioLabs the team has arranged in recent months. In December 2024, they represented next-generation drug discovery platform Waypoint Bio in its lease at Alexandria.

Said Burrus, 鈥淚t鈥檚 incredibly rewarding to help cutting-edge companies like 91制片厂 find a home that supports their mission. Securing space for them at the Alexandria Center^庐 for Life Science required a deep understanding of both their scientific needs and the competitive life sciences market in New York. Alexandria provides them a collaborative ecosystem and premier facilities designed for high-growth biotech.鈥�

JLL is a leader in the New York tri-state commercial real estate market, with more than 4,800 of the most recognized industry experts offering brokerage, capital markets, property/facilities management, consulting, and project and development services.

The post Biotech start-up 91制片厂 relocates to Alexandria Center庐 for Life Science 鈥� New York City appeared first on 91制片厂.

Oxford-based , a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed as CEO.聽

As Founder of Ochre, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease 鈥� developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug candidates towards the clinic.

With two major pharma partnership deals with GSK and Boehringer Ingelheim underway, Ochre is identifying disease modifying targets and RNA therapies that have the potential to reverse fibrosis, cirrhosis and other end-stage liver diseases. Ochre is driving progress in a space that has long lacked options for patients by use of its world leading liver perturbation atlases. 

Eliot Forster, Ph.D, Chair of the Board of Directors at Ochre said: 鈥淚鈥檓 delighted to announce Quin鈥檚 appointment as CEO of Ochre. Quin鈥檚 appointment is excellent news for Ochre, its investors and the treatment of liver diseases. I鈥檓 personally delighted to continue to work with Quin and look forward to even greater progress under his leadership.鈥� 

Quin has dedicated his life鈥檚 work to finding breakthrough treatments for late stage liver disease. With his medical training, and degrees in genetics and mathematics from Oxford and Cambridge Universities, Quin founded his first drug discovery company in liver genomics 20 years ago. He鈥檚 since made significant steps in researching the genetic drivers of chronic liver disease and pioneering novel treatments. 

Now, at Ochre, Quin oversees the world鈥檚 largest perfused liver lab in New York, where the company is using human models to make AI-incorporated drug discovery a clinical reality.

, Founder and CEO at 91制片厂, said: 鈥�We started Ochre almost six years ago with a simple mission: to rewrite the future for people living with chronic liver disease. I could not be more thrilled to now be steering our therapies towards the clinic. Getting medicines to patients has been a deeply personal journey of twenty years in liver research.鈥�

The post Dr Quin Wills Appointed as 91制片厂 CEO appeared first on 91制片厂.